Equity Profile

GSK

GSK plc

Health CarePharmaceuticals$104.7B

Apr29Wed

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

GSK plc is a global healthcare company focused on pharmaceuticals and vaccines. With a market cap of $105 billion, GSK plays a significant role in addressing health challenges worldwide, particularly in areas like respiratory diseases and infectious diseases.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well GSK is managing its costs and revenues.

$1.16

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK faced challenges with earnings falling short of expectations. The company has been focusing on improving its product pipeline and addressing supply chain issues.

Management Promises & Guidance

Commitment to advancing its vaccine development programs.
Focus on cost management to improve profitability.
Plans to enhance research and development efforts.

Expectations

Wall Street Expectations

Analysts expect GSK to report earnings that meet or slightly exceed expectations, driven by strong sales in its vaccine segment. However, there are concerns about ongoing supply chain issues affecting overall performance.

Bull Case

If GSK can demonstrate strong revenue growth and effective cost management, it could lead to a positive market reaction, reflecting confidence in its recovery strategy.

Bear Case

If GSK misses earnings expectations again, it may raise questions about its operational efficiency and future growth prospects, leading to a negative market response.

Key Metrics to Watch

EPS

$1.16

Earnings per share is a key indicator of profitability and will show how well GSK is managing its costs and revenues.

Revenue

$7.6B

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK's EPS meet or exceed the consensus estimate of $1.16?

This figure will be critical in assessing the company's profitability and operational efficiency, influencing investor sentiment.

What are the revenue expectations for GSK's vaccine segment?

Given the importance of vaccines in GSK's portfolio, any guidance on this segment will be closely watched for future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for GSK's vaccine sales to outperform expectations due to recent positive trends in public health initiatives.

Supporting Evidence

The options market is pricing a 9.71% move, indicating expectations of higher volatility than historical averages.

GSK's recent investments in R&D could yield better-than-expected results in their vaccine segment.

Key Risk

If GSK's vaccine revenue significantly exceeds expectations, it could challenge the current consensus outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on GSK's ability to meet earnings expectations and provide positive guidance on its vaccine sales.

Bull Confirmed If

Achieving an EPS of $1.16 or higher would confirm the bull case and suggest effective cost management.

Bear Confirmed If

An EPS below $1.15 would support the bear case, indicating ongoing operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±9.71%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±9.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (39K)P/C Ratio: 2.84Puts (15K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a modest positive reaction, possibly confirming the company's recovery strategy.

In-Line / Cautious

If results are in line with expectations, the stock may see limited movement as investors await further clarity on future guidance.

Miss

A miss could lead to a negative reaction, with historical patterns suggesting a decline of around 0.83%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on vaccine sales and any new contracts or partnerships.
2Details on cost management strategies and their impact on profitability.
3Any changes in guidance for the upcoming quarters.
4Insights into the company's R&D pipeline and upcoming product launches.
5Management's outlook on market conditions and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well GSK is managing its costs and revenues.

$1.16

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK faced challenges with earnings falling short of expectations. The company has been focusing on improving its product pipeline and addressing supply chain issues.

Management Promises & Guidance

Commitment to advancing its vaccine development programs.
Focus on cost management to improve profitability.
Plans to enhance research and development efforts.

Expectations

Wall Street Expectations

Bull Case

If GSK can demonstrate strong revenue growth and effective cost management, it could lead to a positive market reaction, reflecting confidence in its recovery strategy.

Bear Case

If GSK misses earnings expectations again, it may raise questions about its operational efficiency and future growth prospects, leading to a negative market response.

Key Metrics to Watch

EPS

$1.16

Earnings per share is a key indicator of profitability and will show how well GSK is managing its costs and revenues.

Revenue

$7.6B

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK's EPS meet or exceed the consensus estimate of $1.16?

This figure will be critical in assessing the company's profitability and operational efficiency, influencing investor sentiment.

What are the revenue expectations for GSK's vaccine segment?

Given the importance of vaccines in GSK's portfolio, any guidance on this segment will be closely watched for future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for GSK's vaccine sales to outperform expectations due to recent positive trends in public health initiatives.

Supporting Evidence

The options market is pricing a 9.71% move, indicating expectations of higher volatility than historical averages.

GSK's recent investments in R&D could yield better-than-expected results in their vaccine segment.

Key Risk

If GSK's vaccine revenue significantly exceeds expectations, it could challenge the current consensus outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on GSK's ability to meet earnings expectations and provide positive guidance on its vaccine sales.

Bull Confirmed If

Achieving an EPS of $1.16 or higher would confirm the bull case and suggest effective cost management.

Bear Confirmed If

An EPS below $1.15 would support the bear case, indicating ongoing operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±9.71%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±9.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (39K)P/C Ratio: 2.84Puts (15K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a modest positive reaction, possibly confirming the company's recovery strategy.

In-Line / Cautious

If results are in line with expectations, the stock may see limited movement as investors await further clarity on future guidance.

Miss

A miss could lead to a negative reaction, with historical patterns suggesting a decline of around 0.83%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on vaccine sales and any new contracts or partnerships.
2Details on cost management strategies and their impact on profitability.
3Any changes in guidance for the upcoming quarters.
4Insights into the company's R&D pipeline and upcoming product launches.
5Management's outlook on market conditions and competitive landscape.